Nilkamal Limited has informed the Exchange about change in Management - Continuation of appointment of Mr. Sharad V. Parekh (DIN: 00035747) as the Non-Executive and Non Independent Director of the Company
NILKAMAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nilkamal's board approved audited results for Q4 and FY ended March 31, 2025. Standalone revenue from operations rose modestly to ₹3,23,931.79 lakhs (FY24: ₹3,13,410.96 lakhs), but standalone net profit fell to ₹9,127.08 lakhs from ₹10,731.22 lakhs. Consolidated net profit also declined to ₹10,680.53 lakhs from ₹12,243.19 lakhs. Standalone EPS for the year stood at ₹61.16 vs ₹71.91 last year. The board recommended a final dividend of ₹20 per share (200%) on the ₹10 face value, subject to shareholder approval, payable on or after July 25, 2025. Mr. Sharad V. Parekh was re-appointed as Non-Executive, Non-Independent Director and Chairman for 4 years (Aug 15, 2025 to Aug 14, 2029). The company also appointed M/s N.L. Bhatia & Associates as Secretarial Auditor for 5 years and announced acquisition of the healthcare business of Imedfurns Private Limited for ₹4 crores via a Business Transfer Agreement. The 39th AGM is scheduled for July 18, 2025 via video conferencing.
Mixed signals for shareholders: revenue growth was accompanied by a decline in profits and EPS year-on-year, but the company is rewarding investors with a healthy 200% dividend. The chairman's continuation provides leadership stability, while the small healthcare acquisition is a minor diversification move unlikely to move the needle.